Transcode Therapeutics (RNAZ) Capital Expenditures (2021 - 2024)

Transcode Therapeutics' (RNAZ) quarterly Capital Expenditures came in at $500.0 in Q4 2024, down 96.11% on a QoQ basis from $12870.0 in Q3 2024.

Transcode Therapeutics (RNAZ) Capital Expenditures (2021 - 2024) Analysis & Trends

Transcode Therapeutics (RNAZ) has 4 years of Capital Expenditures data on file, last reported at $500.0 in Q4 2024.

Quarterly Capital Expenditures changed N/A year-over-year to $500.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $21761.0 (down 38.89% YoY) and the FY2025 annual result came in at $6660.0, down 69.39% from the prior year.
Capital Expenditures fell to $500.0 in Q4 2024, from $12870.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $85728.0 in Q4 2021 to a low of $500.0 in Q4 2024.
A 4-year average of $29507.8 and a median of $20173.5 in 2021 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 179.42% in 2024, down 74.84% in 2024.
Tracing RNAZ's Capital Expenditures over 4 years: stood at $85728.0 in 2021, then sank by 67.09% to $28215.0 in 2022, then slumped by 83.68% to $4606.0 in 2023, then sank by 89.14% to $500.0 in 2024.
The last three Capital Expenditures figures came in at $500.0 (Q4 2024), $12870.0 (Q3 2024), and $4555.0 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	138.81 Bn	130.96 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	86.07 Bn	78.08 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	65.47 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	55.64 Bn	50.50 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.99 Bn	36.89 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.68 Bn	28.37 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	27.69 Bn	9.29 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	251.02 Mn
10	Transcode Therapeutics	2.85 Mn	2.85 Mn	-	-

Download Data